Boomtown

[BlazingStocks]

$ILLR Triller Group’s transformation has begun. With ambitious plans set by Bob Diamond and Kevin McGurn’s leadership, we’re building a unified platform to drive growth and deliver value across sectors. This marks the start of a new chapter. Learn more: agba.com/ir #TrillerGroup #Leadership #Innovation #Transformation #talkcapabilities

$ILLR Triller Group’s transformation has begun. With ambitious plans set by Bob Diamond and Kevin McGurn’s leadership, we’re building a unified platform to drive growth and deliver value across sectors. This marks the start of a new chapter. Learn more: https://t.co/JsogmfFJR4… pic.twitter.com/hLOgUL8yuH

— Triller Investor Relations (@triller_IR) October 21, 2024

[BlazingStocks]

$ADHC - This debt elimination is expected to be reflected on their corporate annual report due September 30, 2024.
https://finance.yahoo.com/news/american-diversified-holdings-corporation-announces-100000174.html

[BlazingStocks]

$ILLR Article October 16, 2024

Triller Hits NASDAQ After Merger with AGBA Group Completes — TikTok Competition on the Horizon?
https://www.digitalmusicnews.com/2024/10/15/triller-nasdaq-agba-group-merger/

[Golden Cross]

$ILLR Opportunity for Triller to take market share from TikTok!!!

[BlazingStocks]

$ADHC - announce the completion of the previously announced acquisition of GlucoGuard, a revolutionary AI-driven medical device technology from IMD Solutions, Phoenix, AZ.
https://finance.yahoo.com/news/american-diversified-holdings-corporation-adhc-130000357.html

[Zardiw]

🔥🔥 $TWG Gain 288% #DDAmanda Video Analysis - #1 Stock Screener / Scanner

Z

[Golden Cross]

$AGBA **Merger_Of_The_Year** = Triller + AGBA = ILLR
~ Forging A New Path Ahead ... Chance to still get in before
merger closes Monday after the close!⚡️💯

[Golden Cross]

💲 $AGBA & TRILLER Merger Getting A Lot Of Attention! Many Catalysts Lined Up Heading Into The Merger. 💫

[BlazingStocks]

#Nasdaq ~ $AGBA
$CVKD $OCTO $SOXS $NVDA $STEN $DELL $TMF $SOXL $WMT $LGF.A $CHWY $FIAT $GOOGL $BTG $FFIF $TSLA $UPST $TSLL $AAPL $NVDL @agbagroup @triller @FiteTV @Sony @TheNotoriousMMA #Triller #Wealth #Insurance #Investment #Securities #Properties #Healthcare 

[BlazingStocks]

$AGBA News September 03, 2024

Agba and Triller Announce Amended and Restated Merger Agreement
https://finance.yahoo.com/news/agba-triller-announce-amended-restated-130000846.html

[BlazingStocks]

$AGBA - The shares issued as a result of the Share Split will be distributed on the Payment Date. Fractional shares will not be issued and will be rounded up to the next whole share.
https://www.otcmarkets.com/filing/html?id=17870688&guid=RdL-kHvy7FA_B3h

[Golden Cross]

$AGBA Manole Capital Management Discusses AGBA and Triller Mega Merger on SeekingAlpha.com

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)

Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression

Ketamine is currently used off-label for this indication. However, FDA approval is typically required for patients to obtain insurance reimbursement

NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use

RADNOR, Pa., Sept. 30, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today announced that twelve-month real-time stability on the first manufactured lot of NRX-100 (Ketamine) at Nephron Pharmaceuticals, utilizing commercial scale processes, was reached on September 24, 2024. In this process, no degradation of the active ingredient was observed. These findings are consistent with projected room temperature shelf stability in excess of three years. Accelerated stability on additional manufactured lots of preservative-free product is congruent with stability seen in this initial lot.

Demonstrating the ability to manufacture drug product, and prove its stability, are critical components of the drug approval process with the US FDA. Filing of the NDA for NRX-100 is on track for 2024. The NRX-100 formulation is the first sterile, single dose vial prepared with without the addition of preservatives, which may have toxic effects with repeated use.

"We are pleased to reach this important milestone in our preparation of the NDA for NRX-100, a drug we believe can significantly benefit the 3.8 million people who make a plan to commit suicide in the United States each year1," said Jonathan Javitt, MD, MPH, Chairman and Chief Scientist of NRx Pharmaceuticals. "I would like to congratulate the manufacturing team from our partner Nephron Pharmaceuticals for helping us take this important step forward in bringing hope to life."

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 inpatients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
[e-mail]

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
[e-mail]

_________________________
1 https://www.cdc.gov/suicide/facts/data.html

https://c212.net/c/img/favicon.png?sn=CL18716&sd=2024-09-30 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-announces-completion-of-twelve-months-of-stability-on-the-first-manufactured-commercial-scale-lot-of-nrx-100-ketamine-302262032.html

SOURCE NRx Pharmaceuticals, Inc.

[BlazingStocks]

$AGBA News June 12, 2024

AGBA/Triller $4bn Merger: The Group files its Preliminary Proxy Statement
https://finance.yahoo.com/news/agba-triller-4bn-merger-group-122000311.html

[Golden Cross]

$XXII Solid bottom here and ready for a bounce! Think we can see a double here soon!

[BLULLISH]

PENNYLAND EXPECTED SOON —>>>- PENNYLAND BOOOM-https://www.barchart.com/stocks/quotes/ICBU/opinion

$ICBU https://www.riizehealth.com/

BREAKOUT TO PENNYLAND COMING-https://www.tipranks.com/news/press-releases/imd-companies-inc-signs-letter-of-intent-to-acquire-healthcare-company-riize-llc

ACQUISITION-COMPLETED AS PROMISED-https://www.tipranks.com/news/press-releases/imd-companies-inc-completes-acquisition-of-riize-llc

MAJOR ACQUISITION EXPANSION UPDATES COMING FAST-https://www.tipranks.com/news/press-releases/imd-companies-inc-subsidiary-riize-llc-to-expand-product-line-with-contracted-telemedicine-doctors


AMAZING 🤩 CHART— https://www.barchart.com/stocks/quotes/ICBU/opinion

🤩

[Golden Cross]

$AGBA - Triller $4 Billion Merger: Elevating Shareholder Value to New Heights – Immediately and for the Longer Term

[ProfitScout]

$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com

"How NRx Could Upend the Fight Against Depression and Suicide"

RADNOR, Pa., Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found here. The author notes:

"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."
"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."
"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."
For more information, please visit http://www.nrxpharma.com.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
[e-mail]

Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
[e-mail]

https://c212.net/c/img/favicon.png?sn=CL03022&sd=2024-09-11 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-featured-on-psychiatristcom-302244304.html

SOURCE NRx Pharmaceuticals, Inc.

[BlazingStocks]

$BHAT - Blue Hat Interactive Entertainment Technology Summary, Valuation, and Chart
https://www.marketscreener.com/quote/stock/BLUE-HAT-INTERACTIVE-ENTE-62745753/

[Value_Investor]

KXIN (NASDAQ-Exchange stock) is at Hyper Oversold status now --- from May 17's pre-market high $0.6 to last Friday's daily low $0.0745 which is 88% Huge price crash within just a few months!

Easy to surge back to $0.6 again based on its Huge Book Value --- $0.9842 a share!

Note, the 52-week-high is $5.5185 which is 9.2 Times of $0.6!

[BlazingStocks]

$BHAT - Originally an entertainment company, Blue Hat is now focusing on innovations in the commodity trading arena. The company is planning to integrate artificial intelligence to enhance its offerings, including an intelligent gold supply chain and recycling system, as well as a sophisticated gold derivatives trading platform.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html

[Value_Investor]

AFFL just created a New 52-week-high $0.1 yesterday! The AS was diluted to 500M shares now from last June's 50M shares and the OS was diluted to 75.6M shares from 24.6M shares!

The 52-week-low is $0.0020!

[Value_Investor]

ASTI did Rapidly bounce to $5.29 from $2.7 after 1:100 Big R/S! A good NASDAQ stock to trade with!

[Alexulf]

t's HAPPENING! Gold & Silver to Blow Through the Roof -
with precious metals stock investor Peter Schiff

Two stocks to consider now; Euro Sun Mining https://www.barchart.com/stocks/quotes/ESM.TO/overview

and; https://www.barchart.com/stocks/quotes/BBBXF/overview

BOTH STOCKS ON OTC AND TSX

[Value_Investor]

PLUM seems bottomed out at $1.55. It had already bounced up over 77% most recently! Good chance to test $3 or above!

[Value_Investor]

TNXP has bounced Up 110.3% today after Good News --- from $0.4021 to $0.8456! Last January it did Quickly surge 5.2-Bagger to Pre-R/S's $1.456 from Pre-R/S's $0.28 --- see the first chart below!

This Hidden Gem is also at Hyper Oversold status --- from May 17's high $6.72 to Super-Ridiculous-Low $0.4021!

This Diamond_In_Rough has Shocking Huge Positive Book Value (BV) --- $1.92 a share!

So, TNXP is Super Undervalued now! Easy to surge over Pre-R/S's Bottom $3.84!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio 4.8!

There is a 4.5412-Bagger Huge Price-Gap between Pre-R/S's Bottom $3.84 and today's high $0.8456! So, we'll soon see a 5.2-Bagger+ Easy & Quick Rally again!

Note, the 200-Day MAL is at $8.00 from the second chart below!

Hopefully the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger+ Huge Rally...

[Value_Investor]

KGRI will soon be Up-Listed to the Pink-Sheet Market just like its OTC peers (such as AFFL, BRLL, and MNGG etc.) did recently! This Hidden Gem had already reduced its AS to 560,000,000 shares from 5,000,000,000 shares! And the OS was reduced to 423,286,629 shares! The Diamond-In-Rough owns a Key CANNABIS-related US-Patent! The Highest-Trading-Volume (HTV) is measly 359,571,358 shares in its Entire trading history!

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174287653

It will be Very Easy for KGRI to Quickly surge over its recent high 0.0015 and to create A Series Of New 52-Week Highs based on its peer's market value at their peaks!

Because buying its peer (BRLL: 382,837,825/450,000,000 shares OS/AS) at $3.00 = buying KGRI at $2.7134 which is 1809 Times of its recent high 0.0015!

Buying its peer (ITVI: 24,572,500,746/30,000,000,000 shares Giant OS/AS) at $0.0019 = buying KGRI at $0.1103 which is 74 Times of its recent high 0.0015!

Buying its peer (HPIL: 38,132,535,775/40,000,000,000 shares Giant OS/AS) at $0.0119 = buying KGRI at $1.0721 which is 715 Times of its recent high 0.0015!

Buying its peer (MNGG: 7,615,161,617/9,000,000,000 shares Huge OS/AS) at $0.0011 = buying KGRI at $0.0198 which is 13.2 Times of its recent high 0.0015!

Buying its peer (AFFL: 74,554,166/500,000,000 shares OS/AS) at $0.089 = buying KGRI at $0.01567 which is 10.5 Times of its recent high 0.0015!

So, KGRI is Super Undervalued now and it is Much-Much-Much-Much-Much Cheaper than BRLL, ITVI, HPIL, MNGG, AGBA, and AFFL etc. peers!

Note: HPIL and ITVI all have Billions shares of Huge HTV v.s. KGRI only has 0.3B shares of Tiny HTV!

[ProfitScout]

$SHOT News: Safety Shot Announces Powerful Data Analysis From Recent Clinical Trial Confirming Dramatic Reduction of Blood Alcohol Content

First-of-its-kind wellness company Safety Shot announces clinical trials solidifying the brand's dietary supplement's ability to significantly reduce Blood Alcohol Content

JUPITER, Fla., Aug. 12, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company"), the revolutionary wellness and dietary supplement company dedicated to the promotion of responsible consumption of alcohol, announces significant new findings from a recent clinical trial conducted at The Center for Applied Health Sciences ("CAHS"). The double-blind, randomized, placebo-controlled study evaluated the acute impact of Safety Shot on consumer's Blood Alcohol Content ("BAC"), successfully demonstrating remarkable and statistically significant results in various measures related to alcohol consumption and the subsequent rapid reduction of BAC.

The study found that within 30 minutes [of the consumption of Safety Shot], monitored participants reported a highly significant drop in BAC and peak changes in several of the markers responsible for the metabolism of alcohol. Participants between the ages of 24 and 46 with bodyweight ranging between 95 and 225 lbs. showed a dramatic and remarkable difference of 30%-50% faster in the rate at which alcohol was reduced and cleared from the body with the consumption of Safety Shot over the placebo. Participants continued to see measurable drops in successive 30-minute increments, indicating Safety Shot's proprietary blend of vitamins, minerals and botanical ingredients is clinically proven as the world's first formula to aid in the rapid reduction of alcohol within the body.

"This marks a significant change in consumer behavior by providing a safer experience to consume alcohol, as well as better controlled drinking habits to allow for a healthier and more enjoyable environment for the consumer. We are thrilled to finally share the news that after nearly a decade of research and development, our study has successfully confirmed what we have seen in many of our own non-clinical trials," said Chief Operations Officer and co-inventor, David Sandler. "These results are revolutionizing the wellness space as we continue to pioneer the world's most innovative functional beverages," continued Sandler.

Key Findings:

Breath Alcohol Content: Safety Shot proved to consistently lower breath alcohol content at all measured time points compared to the placebo.
Blood Alcohol Content: The study found significant improvements in BAC in the area under the curve (AUC) and maximum concentration (Cmax) for ethanol, acetaldehyde, and aldehyde dehydrogenase levels, favoring Safety Shot.
Physical Results: Trial participants reported significantly less head discomfort, reduced fatigue, increased energy levels, improvements in concentration and reduced feelings of tiredness at multiple time points throughout the study.
These groundbreaking findings indicate Safety Shot's efficacy in supporting user metabolism to reduce BAC and ultimately enhance subjective feelings of well-being and physiological responses post-alcohol consumption. The study's results are currently being compiled into a manuscript, which will be submitted to a biomedical journal for peer review and publication.

Dr. Tim Ziegenfuss, CEO of CAHS stated, "These results are highly encouraging, showcasing Safety Shot's potential as a beneficial supplement for individuals consuming alcohol. The observed reductions in breath and blood alcohol levels, along with the improvements in subjective feelings and physiological measures, highlight the promise of Safety Shot in supporting better outcomes in post-alcohol consumption."

For more information about Safety Shot and the full details of the study, please visit http://www.drinksafetyshot.com.

About Safety Shot, Inc.
Safety Shot, Inc. a wellness and dietary supplement company dedicated to the promotion of responsible drinking, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars throughout 2024.

About CAHS
The Center for Applied Health Sciences is an industry leading CRO (Contract Research Organization) that is committed to providing cost-effective, customized research solutions to suit the needs of natural products, dietary supplements, functional food and beverage industries. www.thecahs.com

Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding Safety Shot's ability to develop and commercialize a product that lowers blood alcohol content, the timing, progress and results of non-clinical studies and clinical trials, including our product development plans and strategies, Safety Shot's future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Safety Shot's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our ability to comply with applicable U.S. and foreign laws, rules, and regulations, product liability claims, our ability to develop and market Safety Shot and the risks and uncertainties that are described more fully in the section titled "Risk Factors" in Safety Shot's annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission on April 1, 2024, and its other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Safety Shot undertakes no duty to update such information except as required under applicable law.

https://c212.net/c/img/favicon.png?sn=LA81625&sd=2024-08-12 View original content to download multimedia:https://www.prnewswire.com/news-releases/safety-shot-announces-powerful-data-analysis-from-recent-clinical-trial-confirming-dramatic-reduction-of-blood-alcohol-content-302219890.html

SOURCE Safety Shot

[Zardiw]

$TENK +247%+ #DDAmanda Video Analysis - #1 Stock Scanner/Screener

Z

[Bansky]

$EBYH news out

https://finance.yahoo.com/news/strainsforpains-ebyh-ceo-simon-shainberg-100000188.html

What is the new partnership announced by Strainsforpains (EBYH)?
Strainsforpains (EBYH) has signed a strategic product commercialization agreement with Cannabis Science for international retail and wholesale cannabinoid drug distribution.

What are the projected sales for Strainsforpains (EBYH) in 2024?
Strainsforpains (EBYH) projects to surpass $500,000 in sales for 2024, based on recent orders and expanding partnerships.

What key products are included in the Strainsforpains (EBYH) and Cannabis Science partnership?
The partnership includes Cannabis Science's Harvard Award-winning cancer research and CBN patent for sleep and neurological disorders, as well as Strainsforpains' existing CBD product line.

How much in orders has Strainsforpains (EBYH) received recently?
Strainsforpains (EBYH) has received orders totaling $195,000, with $65,000 in Q4 2023 and $130,000 in early 2024.

[ProfitScout]

$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals (Nasdaq:NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff

Petition for a temporary restraining order brought by Streeterville Capital, LLC seeking injunctive relief to prevent spinoff of 49% of HOPE Therapeutics shares to current NRx Shareholders has been denied by Utah arbitrator.

Petition by Streeterville Capital, LLC seeking injunctive relief to prevent sales of NRx shares has been denied by Utah arbitrator.

NRx to proceed with spinoff of HOPE Therapeutics as previously announced.

RADNOR, Pa., July 29, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical stage pharmaceutical company, today announced the issuance of an order by a Utah arbitrator denying the petition of Streeterville Capital, LLC to enjoin NRx's planned spinoff of 49% of the shares in HOPE Therapeutics to current shareholders of NRx pharmaceuticals. While the proposed spinoff remains subject to compliance with certain disclosure and other requirements under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, the spinoff is intended to provide NRx shareholders with an opportunity to participate in the anticipated value created as a result of the spinoff and to enable a potential listing of HOPE Therapeutics (currently a wholly-owned subsidiary of NRx) on a national securities exchange. The arbitrator also denied Streeterville's petition to enjoin NRx from selling additional shares of NRx stock to finance ongoing operations.

(PRNewsfoto/NRx Pharmaceuticals)

"As we have previously shared with the public, HOPE Therapeutics is in the process of developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression. This arbitration decision enables us to keep our promise to shareholders to spin out 49% of HOPE Therapeutics shares held by NRx to our shareholders, subject to approval by our Board of Directors and compliance with applicable law. We appreciate the support and loyalty of our shareholders as we work to bring HOPE to life," said Prof. Jonathan Javitt, Founder and Chairman of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a care delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-nasdaqnrxp-announce-arbitration-order-enabling-hope-therapeutics-spinoff-302208316.html

SOURCE NRx Pharmaceuticals, Inc.

[Alexulf]

Excellent entry point/refill - goldprice start moving up again - and so do the stock as well.
https://www.barchart.com/stocks/quotes/BBBXF/overview OTC
https://www.barchart.com/stocks/quotes/BBB.VN/overview TSX
Given goldprice climbing, silver resource awareness, high grade results from last update... things are moving!

https://brixtonmetals.com/

Maybe I´m wrong - still, I believe in a similar meltup as in 2016 this year/early 2025

[BlazingStocks]

$AGBA News July 05, 2024

AGBA Group, one of Nasdaq’s top 10 best-performing stocks for 2024, further cements strategic partnership with Yorkville
https://finance.yahoo.com/news/agba-group-one-nasdaq-top-130000537.html

[Golden Cross]

$IFUS GLP-1 Muscle Mass Loss Buoys the Protein Trade: INGR TSN ZTS IFUS
https://www.insiderfinancial.com/post/glp-1-muscle-mass-loss-buoys-the-protein-trade-ingr-tsn-zts-ifus

Other Mentions Stocks: $IGNR $ZTS $TSN $ADM $CALM $NATH $TSN $HRL $MDLZ $PEP $NOVO $LLY

[BlazingStocks]

$AGBA - Since going public via a SPAC in November 2023, AGBA's team of over 1,500+ employees has worked tirelessly everyday in delivering steady growth persistently quarter after quarter maintaining our market leadership.
https://finance.yahoo.com/news/empowering-shareholders-agbas-us-4b-130000814.html

[Golden Cross]

$OCTO Undervalued here...

[BlazingStocks]

$AGBA - AGBA is making excellent progress in preparing its proxy statement regarding the proposed merger. AGBA expects to file its preliminary proxy statement with the SEC in early June 2024.
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[BlazingStocks]

$OCTO
The Company currently has approximately 8.8 million shares outstanding, resulting in a market capitalization of approximately $4.0 million based on the closing price of the Company’s common stock on June 28, 2024. Management believes the current market capitalization may not fully reflect the Company's substantial progress in enhancing shareholder equity and operational efficiencies described above.

[Golden Cross]

$EWRC News next week on current and future projects. Details on the upcoming release of their game, Last Seen; Last Night, on the Epic Games store (7/7). Steady accumulation here.

$EWRC’s press release next week will encompass current and future projects. It will also include our 1st person POV game schedule with a detailed roadmap with one of the gaming world’s premiere platforms.

— eWorld Companies, Inc (@eworld_company) June 28, 2024

[Value_Investor]

AFFL has $18.3515 Analyst's Target based on its Current-Information-tier peer's MV at its recent high $4.1! Once the Upcoming Reverse-Merger deal kicks in, this hidden gem (24,554,116 shares Tiny OS and 250M shares Tiny AS) will soar to $18.3515 in order to match the Same MV with SSHT (109,903,473 shares Large OS and 1B/1000M shares Huge AS) at its peak!

Note, the Analyst's Target $18.3515 = 206.2 Times of its recent high $0.089!

This CLEAN Shell has a Sought-After FIXED Tiny Shares-Structure and a Super-Positive Neat Financial Balance Sheet! It is easy to be Up-Listed to the NASDAQ Exchange after the Upcoming Reverse-Merger deal……

Buying its OTC-CI-tier peer (BDCC) at 52-week-high $27.747 = buying AFFL at $64.409 which is 2012.8 Times of Super-Ridiculous-Low 52-week-high $0.032!

Buying its OTC-CI-tier peer (BDCC) at current price $0.82 = buying AFFL at $1.9035 which is 67.3 Times of current Super-Ridiculous-Low price $0.0283!

Buying its OTC-CI-tier peer (BDCC) at 52-week-low $0.22 = buying AFFL at $0.5107 which is 255.4 Times of Super-Ridiculous-Low 52-week-low $0.002!

AFFL is Super Undervalued now --- Mere $694,881 MV at current Super-Ridiculous-Low price $0.0283 v.s. its Same CI-tier but Much-Worse peer is trading at Shocking-High $104,408,299 MV now!

AFFL is at Hyper Oversold status --- from its Record-High $6 to current Super-Ridiculous-Low price $0.0283!

In fact, AFFL ever hit a Historic-Record-High $6 with 67,801,926 shares of Old OS Count! But AFFL only has 24,554,116 shares of New OS Count now! So, it will create a New Historic-Record-High $16.568 in order to have the Same Market Value as before!

[BlazingStocks]

$SFWJ News June 12, 2024

SFWJ/MedCana Announces Strategic Partnership with Colombian Company to Begin Exporting CBD Buds to Switzerland
https://finance.yahoo.com/news/sfwj-medcana-announces-strategic-partnership-134500645.html

[ProfitScout]

$RENB Renovaro, Amsterdam UMC Cancer Center Plan to Form Joint Venture for Cancer Immunotherapy
Click here:
https://www.marketscreener.com/quote/stock/RENOVARO-INC-47536345/news/Renovaro-Amsterdam-UMC-Cancer-Center-Plan-to-Form-Joint-Venture-for-Cancer-Immunotherapy-46820158/ @Nasdaq @Marketscreener1 #collaboration

[Alexulf]

ESM Responds to EU Commission Call For Strategic Mining Projects!

https://ceo.ca/@globenewswire/euro-sun-mining-responds-to-european-commission-call

Part of article;

ESM wishes to confirm that the Company has formally begun proceedings to list its Rovina Valley Project (the “Project”)
with the European Commission as a “strategic project” for the European supply of critical minerals.

Following a meeting held on May 27, 2024 with the Romanian Ministry of Economy, the application for the Project to be
designated as a “strategic project” within the European Commission’s Critical Raw Materials Act was sanctioned.

This positive development will take place whilst Romania continues towards overhauling its
existing mining legislation to align with the Critical Raw Materials Act.

IMO very important news, yet the market do not react (so far?), with a gain in the share price - maybe a delayed effect will play out.

With the project officially supported by the EU commision, the Romanian side will also play ball - no more stalling -
cause now it`s in the interest of the new government to succeed with it, not only the company itself -
the CEO`s 4% stake of OS is also a significant fact that will pay of to shareholders.

BULLISH

[BlazingStocks]

$BDCC - A product of prestigious universities, Mohammed's academic background in Civil Engineering serves as the bedrock of his illustrious career, providing him with the technical proficiency and strategic insight necessary to navigate the complexities of the industry with unparalleled finesse.
https://finance.yahoo.com/news/blackwell-3d-corporation-secures-services-040533630.html

[BlazingStocks]

$AGBA News May 21, 2024

AGBA/Triller $4bn Merger: Excellent Progress Ahead of Plan
https://www.marketwatch.com/press-release/agba-triller-4bn-merger-excellent-progress-ahead-of-plan-fbd7e5fe?mod=mw_quote_news_seemore

[ProfitScout]

$SHOT: Safety Shot Partners with Capital Drugs To Launch World's First Beverage To Reduce Blood Alcohol Content in 300 Pharmacies Across the Country

The First of its Kind Vitamin-Packed, Wellness Beverage Brand Continues to Amplify its In-Store Availability Nationwide

JUPITER, Fla., June 6, 2024 /PRNewswire/ -- Safety Shot, Inc. (Nasdaq: SHOT) (the "Company), announced today its partnership with Capital Drugs as the brand expands its nationwide availability. Making strides in connecting the brand to its overarching wellness purpose, Safety Shot will be available in all 300 of the drugstore chain's pharmacies across the United States.

Entering a key market for Safety Shot consumers, Capital Drugs is known for providing a wide range of pharmaceutical services and products tailored to specific health and wellness needs. Capital Drugs offers traditional pharmacy and clinical services in tandem with alternative medicine options such as supplements, vitamins, and homeopathic products.

"Entering Capital Drugs pharmacies is an integral next step in furthering Safety Shots key messaging and purpose of operating as a functional wellness beverage," said Josh Wagner, Chief Revenue Officer at Safety Shot. "Expanding on-shelf availability and having the product available for purchase in key locations like Capital Drug pharmacies is the brand's core mission, introducing the first-of-its-kind beverage to a like-minded consumer audience."

This latest affiliation aligns with the brand's comprehensive nationwide availability rollout and partnership expansion plan. This announcement comes on the heels of its Northeast expansion across New York and New Jersey through boutique broker Prime CBS and additional partnerships with GoPuff, BevMo and more.

About Safety Shot, Inc

Safety Shot, Inc., a wellness and dietary supplement company, has developed Safety Shot, the first patented wellness product on Earth that lowers blood alcohol content by supporting its metabolism, while boosting clarity, energy and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The Company is introducing business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars throughout 2024.

SOURCE Safety Shot

[Value_Investor]

ASTI did Rapidly surge to $0.203 from $0.1131 on June 3! However, it crashed down to $0.095 today! So, it may Quickly bounce up to test $0.2xxx again as soon as the coming week...

ASTI is currently at Extremely Oversold status --- from its most Recent high $0.34 (on May 23) to current Ridiculous-Low price levels $0.09xx!

[Value_Investor]

TTNXP was Up over 21% in After-Hour session on June 13 after Good News (see the link below)! Last January it did Quickly surge 5.2-Bagger to Pre-R/S's $1.456 from Pre-R/S's $0.28 --- see the first chart below!

https://www.otcmarkets.com/filing/html?id=17619193&guid=cqQ-kamb8r4T4rh

This Hidden Gem is also at Hyper Oversold status --- from May 17's high $6.72 to June 13's Super-Ridiculous-Low price $1.08!

This Diamond_In_Rough has Shocking Huge Positive Book Value (BV) --- $36.22 a share which is 33.54 Times of Super-Ridiculous-Low price $1.08! Also it has Huge Positive Cash Value --- $2.36 a share which is 2.19 Times of Super-Ridiculous-Low price $1.08!

That means that TNXP is Super Undervalued now! Easy to surge over May 17's high $6.72!

TNXP is the Cheapest Bio-Tech NASDAQ stock with the Highest BV/PPS Ratio up to 33.54!

There is a 3.2-Bagger Huge Price-Gap between $3.84 and June 12's high $1.2! So, we'll soon see a 5.2-Bagger+ Easy & Quick Rally again!

Note, the 50-Day MAL is at $5.13 from the second chart below!

Hopefully as soon as next week the company will issue some Very Good News to trigger the Upcoming 5.2-Bagger+ Huge Rally...

[BlazingStocks]

$AGBA News June 12, 2024

AGBA/Triller $4bn Merger: The Group files its Preliminary Proxy Statement
https://finance.yahoo.com/news/agba-triller-4bn-merger-group-122000311.html

[BlazingStocks]

$FAVO News June 11, 2024

FAVO Capital, Inc. Appoints Turner, Stone & Company, LLP as Auditors
https://finance.yahoo.com/news/favo-capital-inc-appoints-turner-171500774.html